SYNVITROBIO, INC.
Cell-free protein expression and purification platform for rapidly producing human SNP variants at scale
- Sector
- Biotech
- Headquarters
- San Francisco, CA
- Latest Form D
- $17.6M, Sep 2023
- Total capital
- $23.3M
- Federal grants
- $2.9M
- 8 awards · 2015–2020
- Rank in peer group#26 of 36
- Private capital raised
- $17.6M
- 1 Form D · last Sep 2023
- 37 months since last filing
- Federal contracts
- $2.8M
- 4 awards · Defense
- Rank in Biotech#114 of 4373
- Granted patents
- 1
- 20 pending · first 2026
- Rank in peer group#10 of 36
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$17.6M
- Federal grantHealth and Human S · Phase I · High-throughput cell-free production of human genetic variants$252K
- Federal contractDefense · STTR Phase II - Biosense, For Identification Of Allosteric Transcription Factor Biosensors$1.0M
- Federal contractDefense · Igf::ot::igf STTR Phase 1$150K
- Federal grantNSF · Phase II · STTR Phase II: An On-Demand, Computational and Microfluidic-Driven Cell-Free Protein Engineering Platform$1.3M
- Federal grantHealth and Human S · Phase I · A functional genomics tool for high-throughput cell-free analysis of regulatory components$276K
- Federal grantHealth and Human S · Phase I · A functional genomics tool for high throughput cell free analysis of regulatory components$276K
Show 6 earlier federal awards
- Federal contractDefense · Igf::ot::igf SBIR Phase I --$150K
- Federal grantHealth and Human S · Phase I · Cell free Expression of Cryptic Actinomycetes Gene Clusters for Natural Products Discovery$225K
- Federal grantHealth and Human S · Phase I · Cell-free Expression of Cryptic Actinomycetes Gene Clusters for Natural Products Discovery$225K
- Federal contractDefense · Igf::ot::igf Darpa Fy 2015.2 Solicitation - SBIR Ph II Titled "rapid, Reliable And Repeatable Platforms For Cell-free Prototyping: A Cell-free Foundry Prototyping Platform"$1.5M
- Federal grantNSF · Phase I · STTR Phase I: An On-Demand Protein Engineering Platform$225K
- Federal grantDefense · Phase I · Rapid, reliable and repeatable platforms for cell-free prototyping$150K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
95months
from SYNVITROBIO, INC.’s first federal award to its first private round.
- First federal award · Oct 2015
- Defense · $150K
- First Form D · Sep 2023
- $17.6M · 1st Form D
- Awards before first raise
- 12 awards
An association in public records, not a cause or a prediction.
Standing among 36 peers
Line = medianBiotech · Platform
- Federal grantsBelow median
- Granted patents#10 · top 28%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Zachary SunResearcherExecutive Officer, DirectorLinked by $1.9M in grants as PI
- Corinna ChenDirectorNamed in SEC Form D filings
- Francisco DopazoDirectorNamed in SEC Form D filings
- Michael NemzekExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 21- PendingMethods For Predicting Cell-free Protein SynthesisUSPTOApplication 19119295
- GrantedMethods and Compositions for Cell-Free Biological ReactionsUSPTOUS 12,559,775
- PendingIn Vitro Transcription/translation (txtl) System And Use ThereofUSPTOApplication 18320389
Show all 21 patent records
- Methods For Predicting Cell-free Protein SynthesisMay 14, 2026 · Application 19119295Pending
- Methods and Compositions for Cell-Free Biological ReactionsFeb 24, 2026 · US 12,559,775Granted
- In Vitro Transcription/translation (txtl) System And Use ThereofFeb 8, 2024 · Application 18320389Pending
- Methods And Systems For Cell-free Biodiscovery Of Natural ProductsFeb 1, 2024 · Application 18311555Pending
- Methods And Compositions For Identifying Traits Using A Cell-free SystemJul 6, 2023 · Application 17802377Pending
- Anaerobic Cell-Free Systems and Environments and Methods for Making and Using SameJun 22, 2023 · Application 16757181Pending
- Improved In Vitro Transcription/Translation (TXTL) System and Use ThereofJun 11, 2020 · Application 16638272Pending
- Methods and Systems for Cell-Free Biodiscovery of Natural ProductsApr 9, 2020 · Application 16499233Pending
- Improved In Vitro Transcription/translation (txtl) System And Use ThereofApplication PCTUS2018046477Pending
- Methods And Systems For Cell-free Biodiscovery Of Natural ProductsApplication PCTUS2018021146Pending
- Methods and Systems for Cell-Free Biodiscovery of Natural ProductsApplication 62620310Pending
- Methods and Arrangements for Anaerobic Cell-free SystemsApplication 62576157Pending
- Extremophile Based Cell-free Systems and Methods for Making and Using SameApplication 62574570Pending
- Vitro Transcription/Translation (TXTL) System and Use ThereofApplication 62544228Pending
- Methods For Predicting Cell-free Protein SynthesisApplication PCTUS2023036595Pending
- Methods For Predicting Cell-free Protein SynthesisApplication 63421784Pending
- Methods And Compositions For Identifying Traits Utilizing A Cell-free SystemApplication PCTUS2021020293Pending
- Methods And Compositions For Maintaining Homeostasis In Cell-free SystemsApplication PCTUS2020021763Pending
- Methods for Identifying Traits Utilizing a Cell-free SystemApplication 62983007Pending
- Methods and Compositions for Maintaining Homeostasis in Cell-Free SystemsApplication 62815445Pending
- Anaerobic Cell-free Systems And Environments And Methods For Making And Using SameApplication PCTUS2018056672Pending
Related companies, and why
- ACTIVE MOTIF, INC.Similar federal contract value in Biotech · $2.9M in contracts
- ARUNA BIO, INC.Similar federal contract value in Biotech · $2.9M in contracts
- STC BIOLOGICS, INCSimilar federal contract value in Biotech · $2.8M in contracts
- EPIBONE, INC.Similar federal contract value in Biotech · $2.8M in contracts
- AGILE SCIENCES, INC.Similar federal contract value in Biotech · $2.7M in contracts
- Amplyx Pharmaceuticals, Inc.Similar federal contract value in Biotech · $2.7M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .